KALARIS THERAPEUTICS INC (KLRS) Stock Income Statement
USA - NASDAQ:KLRS - US4829291065 - Common Stock
6.89 USD
-0.01 (-0.14%)
| TTM (2025-6-30) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Operating Expenses | 47.77M | 55.00M | 181.00M | 171.20M | 169.82M | |||
| Research and Development | 14.54M | N/A | 133.07M | 118.87M | 120.74M | |||
| Selling, General, and Administrative Expenses | 33.22M | 43.00M | 48.00M | 52.33M | 49.08M | |||
| Operating Income | -47.77M | -55.00M | -181.00M | -171.20M | -169.82M | |||
| Interest Income/Expense | 3.03M | N/A | 5.73M | 1.88M | 1.32M | |||
| Other Income/Expense | 1.20M | 6.00M | 3.62M | 350.00K | -2.45M | |||
| Non Recurring Items | -392.00K | -10.00M | -19.00M | N/A | N/A | |||
| Income Before Taxes | -43.94M | -59.00M | -191.00M | -168.98M | -170.96M | |||
| Income Tax | N/A | 0.00 | -130.00K | -270.00K | 1.01M | |||
| Net Income | -43.94M | -59.00M | -190.00M | -168.71M | -171.96M | |||
| EBITDA | N/A | N/A | -180.60M | -170.48M | -169.63M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -6.80 | -11.78 | -1.83 | -2.20 | -2.74 | |||
| Non GAAP EPS | N/A | N/A | -38.41 | -51.75 | -63.02 | |||
| Statistics | ||||||||
| Profit Margin | N/A | N/A | N/A | N/A | N/A | |||
| Operating Profit Margin | N/A | N/A | N/A | N/A | N/A | |||
All data in USD